As of 2025-09-13, the Fair Value of Neovacs SA (ALNEV.PA) is -226.94 EUR. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 0.40 EUR, the upside of Neovacs SA is -56,849.06%.
With the market price of 0.40 EUR and our fair value calculation, Neovacs SA (ALNEV.PA) is not a good investment. Investing in ALNEV.PA stocks now will result in a potential loss of 56,849.06%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -6.14 | -11.84 | -3.55 | -8.74 | -32.91 | -12.64 |
| YoY growth | 18.62% | -92.71% | 70.02% | -146.40% | -276.45% | -85.38% |
| Market Cap (mil) | 0.29 |
| P/E | |
| Forward P/E |
| EPS | -45.39 |
| Avg earnings growth rate | -85.38% |
| TTM earnings | -32.91 |